Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Alvotech and Teva Pharmaceuticals (“Teva”) announced that the U.S. Food and Drug Administration (FDA) has accepted for review ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearingSpeech and development ...

COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet AMDCompany confirms topline results for ...

Interdisciplinary collaboration is key to reducing the risk for osteonecrosis of the jaw and improving patient care.

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...

Topline results for COAST are anticipated in early Q2 2025, with ShORe results expected mid-2025.

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...